The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR
Open accessAbstract
Background and Objective: The Surveillance, Epidemiology, and End Results Program (SEER) program and the National Program of Cancer Registries (NPCR), are authoritative sources for population cancer surveillance and research in the US. An increasing number of recent oncology studies are based on the electronic health record (EHR)-derived de-identified databases created and maintained by Flatiron Health. This report describes the differences in the originating sources and data development processes, and compares baseline demographic characteristics in the cancer-specific databases from Flatiron Health, SEER, and NPCR, to facilitate interpretation of research findings based on these sources. Methods: Patients with documented care from January 1, 2011 through May 31, 2019 in a series of EHR-derived Flatiron Health de-identified databases covering multiple tumor types were included. SEER incidence data (obtained from the SEER 18 database) and NPCR incidence data (obtained from the US Cancer Statistics public use database) for malignant cases diagnosed from January 1, 2011 to December 31, 2016 were included. Comparisons of demographic variables were performed across all disease-specific databases, for all patients and for the subset diagnosed with advanced-stage disease. Results: As of May 2019, a total of 201,570 patients with 19 different cancer types were included in Flatiron Health datasets. In an overall comparison to national cancer registries, patients in the Flatiron Health databases had similar sex, age at initial diagnosis, and geographic distributions but appeared to be diagnosed with later stages of disease compared with patients in other datasets. For variables such as stage and race, Flatiron Health databases had a greater degree of incompleteness. There are variations in these trends by cancer types. Conclusions: These three databases present general similarities in demographic and geographic distribution, but there are overarching differences across the populations they cover. Differences in data sourcing (medical oncology EHRs vs cancer registries), and disparities in sampling approaches and rules of data acquisition may explain some of these divergences. Furthermore, unlike the steady information flow entered into registries, the availability of medical oncology EHR-derived information reflects the extent of involvement of medical oncology clinics at different points in the specialty management of individual diseases, resulting in inter-disease variability. These differences should be considered when interpreting study results obtained with these databases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Cronin, K. A., Ries, L. A. G., & Edwards, B. K. (2014) · Cancer · doi:10.1002/cncr.29049 · Cited by 699
Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.3241 · Cited by 549
Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
Curtis, M. D., Griffith, S. D., Tucker, M., Taylor, M. D., Capra, W. B., Carrigan, G., Holzman, B., Torres, A. Z., You, P., Arnieri, B., et al. (2018) · Health Services Research · doi:10.1111/1475-6773.12872 · Cited by 217
Nattinger, A. B., McAuliffe, T. L., & Schapira, M. M. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00099-1 · Cited by 212
Griffith, S. D., Tucker, M., Bowser, B., Calkins, G., Chang, C.-H. (., Guardino, E., Khozin, S., Kraut, J., You, P., Schrag, D., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00970-1 · Cited by 158
Presley, C. J., Tang, D., Soulos, P. R., Chiang, A. C., Longtine, J. A., Adelson, K. B., Herbst, R. S., Zhu, W., Nussbaum, N. C., Sorg, R. A., et al. (2018) · JAMA · doi:10.1001/jama.2018.9824 · Cited by 140
Khozin, S., Miksad, R. A., Adami, J., Boyd, M. E., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., et al. (2019) · Cancer · doi:10.1002/cncr.32383 · Cited by 136
Eichler, H., Bloechl‐Daum, B., Broich, K., Kyrle, P. A., Oderkirk, J., Rasi, G., Ivo, R. S., Schuurman, A., Senderovitz, T., Slawomirski, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1226 · Cited by 124
How generalizable are the SEER registries to the cancer populations of the USA?
Kuo, T., & Mobley, L. R. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0790-x · Cited by 115
The State of Cancer Care in America, 2015: A Report by the American Society of Clinical Oncology
American Society of Clinical Oncology (2015) · Journal of Oncology Practice · doi:10.1200/jop.2015.003772 · Cited by 103
Steuten, L., Goulart, B. H. L., Meropol, N. J., Pritchard, D. E., & Ramsey, S. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00002 · Cited by 83
Feld, E., Harton, J. G., Meropol, N. J., Adamson, B. J. S., Cohen, A. B., Parikh, R. B., Galsky, M. D., Narayan, V., Christodouleas, J. P., Vaughn, D. J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.032 · Cited by 64
Self-citationNational Program of Cancer Registries
National Cancer Institute (2020) · Definitions · doi:10.32388/sdmgxa · Cited by 58
Parikh, R. B., Galsky, M. D., Gyawali, B., Riaz, F., Kaufmann, T. L., Cohen, A. B., Adamson, B. J. S., Gross, C. P., Meropol, N. J., & Mamtani, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0039 · Cited by 43
Self-citationRohrs, J. A., Wang, P., & Finley, S. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00057 · Cited by 28
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer
Parikh, R. B., Adamson, B. J. S., Khozin, S., Galsky, M. D., Baxi, S. S., Cohen, A. B., & Mamtani, R. (2019) · JAMA · doi:10.1001/jama.2019.10650 · Cited by 21
Self-citationBagley, S. J., Talento, S., Mitra, N., Meropol, N. J., Cohen, R. B., Langer, C. J., & Vachani, A. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7102 · Cited by 20
Parikh, R. B., Feld, E., Galsky, M. D., Adamson, B. J. S., Cohen, A. B., Baxi, S. S., Boursi, S. B., Christodouleas, J. P., Vaughn, D. J., Meropol, N. J., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0578 · Cited by 15
Self-citationWinfree, K. B., Torres, A. Z., Zhu, Y. E., Muehlenbein, C. E., Aggarwal, H., Woods, S., & Abernethy, A. P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1547273 · Cited by 13
Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer
Riaz, F., Presley, C. J., Chiang, A. C., Longtine, J. A., Soulos, P. R., Adelson, K. B., Herbst, R. S., Nussbaum, N. C., Sorg, R. A., Abernethy, A. P., et al. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.01.016 · Cited by 10
Changes underway for SEER: Program leaders work to increase the breadth and depth of information
Printz, C. (2015) · Cancer · doi:10.1002/cncr.29002 · Cited by 2
Cited by
Evaluating eligibility criteria of oncology trials using real-world data and AI
Liu, R., Rizzo, S., Whipple, S., Pal, N., Pineda, A. L., Lu, M., Arnieri, B., Lu, Y., Capra, W., Copping, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03430-5 · Cited by 322
Harnessing Real-World Evidence to Advance Cancer Research
Tang, M., Pearson, S.-A., Simes, R. J., & Chua, B. H. (2023) · Current Oncology · doi:10.3390/curroncol30020143 · Cited by 88
Sun, L., Hsu, M., Cohen, R. B., Langer, C. J., Mamtani, R., & Aggarwal, C. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0546 · Cited by 87
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers
Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23186 · Cited by 44
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Metadata
- Authors
- Ma, X., Long, L., Moon, S., Adamson, B. J. S., & Baxi, S. S.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-03-18
- OpenAlex
- W3011119029
- Cited by
- 353
- References
- 23
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.